Champignon Brands To Acquire Biotech Firm Novo Formulations
Champignon Brands (CSE: SHRM) announced today that they have signed a definitive agreement to acquire that of Novo Formulations Ltd. Novo is a biotechnology focused firm that is currently developing novel and innovative delivery systems for the pharmaceutical and nutraceutical industries.
The acquisition of Novo and their delivery systems platform and R&D advancements is anticipated to compliment Champignon’s current patent portfolio. The Novo roster consists of a number of PhD and technician scientists with decades worth of experience in building novel intellectual property in the medical field. Additionally, the team has vast experience in developing and marketing novel delivery systems.
Presently, Novo is working with a host of pharmaceutical and nutral molecules, as well as ketamine, anaesthetics and adaptogenics. The firm is currently conducting its operations out of a Quebec facility that is licensed for pharmaceutical work, as well as at a pharmacy in Ontario. The company is currently developing, formulating, and commercializing delivery platforms that include trandermal, intranasal, oral, sublingual and suppository methods.
The addition of Novoformulations allows Champignon to deliver medications in a safer, more effective and more expeditious manner than our peers, from bench top in the laboratory, to preclinical and clinical trials. We are intent on the commercialization of products throughout North America, as rapidly as is safely and effectively practicable.
Champignon Chief Executive Officer Gareth Birdsall
Champignon Brands is acquiring Novo for a total purchase price of $3.1 million, which is being satisfied through the issuance of 12.5 million common shares of the issuer. Champignon intends to utilize Novo’s current product development infrastructure to develop psilocybin and MDMA based formulations with the goal of developing rapid onset treaments that are effective against depression, PTSD, and substance and alcohol use disorders.
Champignon Brands last traded at $0.32 on the CSE.
FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
